JASPER THERAPEUTICS, INC. (JSPR) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 36.70M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 4.27M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -55.16M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $36.70M | (m) | $4.27M | $-55.16M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $52.76M | (m) | $5.33M | $-73.03M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $63.10M | (m) | $6.71M | $-83.88M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $71.52M | (m) | $7.02M | $-93.33M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $71.58M | (m) | $7.60M | $-94.05M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $61.68M | (m) | $7.26M | $-82.97M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $55.82M | (m) | $6.62M | $-76.24M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $49.88M | (m) | $5.81M | $-68.68M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $50.28M | (m) | $5.20M | $-68.15M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $52.28M | (m) | $5.11M | $-69.99M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $51.78M | (m) | $5.21M | $-68.86M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $47.23M | (m) | $5.66M | $-64.88M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $41.41M | (m) | $4.91M | $-58.23M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $36.24M | (m) | $4.58M | $-52.37M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $34.63M | (m) | $4.09M | $-51.20M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $34.00M | (m) | $2.72M | $-49.53M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $32.17M | (m) | $2.27M | $-46.90M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $29.19M | (m) | $1.50M | $-43.36M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $25.42M | (m) | $1.05M | $-36.83M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | $-10.96M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-24 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | $-1.16M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | $-921.14K | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | $-935.40K | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-11-21 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-08-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |